Home | Sitemap | Search | Contact A- A A+
   
 
    Public Member Support us  
 

IBCSG 16-98 / BIG 2-97 

Exemestane vs. tamoxifen as adjuvant therapy for postmenopausal women with primary breast cancer who have received adjuvant tamoxifen for 2-3 years

DESIGN

Design Trial 16-98

Results & Publications


Presentations


Posters


Publications

Study Chairs
Dr. Hervé Bonnefoi - Genève, Switzerland
Prof. Alan Coates - Centennial Park, Australia

Trial Coordinator
Melanie Schärlig-Strausak
IBCSG Coordinating Center, Bern, Switzerland
Phone: +41 31 389 93 91
Fax: +41 31 389 92 73
Email: melanie.schaerlig-strausak@ibcsg.org

Date of Activation
May 1998

Date of Closure
August 31, 2001

Targeted Accrual
4400 patients

Final Accrual
4742 patients


Results Publications Results & Publications


News

27.08.2010:
Activation of IBCSG Trial 38-10/BIG 3-07/TROG 07.01

19.08.2010:
A few impressions from our audits

09.08.2010:
Latest SOLE flash

All News

 
  Print